当前位置: X-MOL 学术Brief. Funct. Genomics › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Corrigendum to: CRISPR Cas9 for cancer treatment technology clinical applications and challenges.
Briefings in Functional Genomics ( IF 4 ) Pub Date : 2020-09-23 , DOI: 10.1093/bfgp/elaa018
Xing Cheng 1 , Shaoyi Fan 2 , Chengcai Wen 3 , Xianfa Du 4, 5
Affiliation  

In the originally published version of this manuscript, the spelling of the first author's name was incorrect. The name should be “Xing Cheng” instead of “Xing Chen”. This error has now been corrected online.

中文翻译:

更正为:CRISPR Cas9用于癌症治疗技术的临床应用和挑战。

最初在细菌和古细菌中发现它是一种针对入侵核酸的适应性免疫策略,这种簇状规则间隔的短回文重复相关蛋白(CRISPR-Cas)系统现已被重新用作基因组编辑和其他应用的实用工具[1]。由于其灵活性,简单性,效率和精确性,CRISPR系统在医学中的应用引起了广泛的关注并经历了快速的发展。目前,CRISPR系统已用于筛选新型药物靶标[2],鉴定致病基因[3],建立疾病研究模式[4],开发针对各种疾病的疗法[5、6]等。
更新日期:2020-09-23
down
wechat
bug